Metabolic syndrome and cardiovascular disease
Authors:
J. Špinar 1; J. Vítovec 2
Authors‘ workplace:
Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC
1; I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
2
Published in:
Vnitř Lék 2009; 55(7-8): 653-658
Category:
134th Internal Medicine Day - 23rd Vanysek's Day Brno 2009 - Vanysek's Lecture
Overview
We provide an overview of the current views on the association between metabolic syndrome and cardiovascular disease. Insulin resistance, frequently onsetting from obesity and associated hypercholesterolemia, hypertension and diabetes mellitus, is the common denominator. We also highlight another risk factor – heart rate, closely related to the prognosis of healthy individuals, patients with hypertension and patients following myocardial infarction. Finally, we present the results of the CRUSADE study that has clearly described the association between obesity and age and the first manifestation of the ischemic heart disease.
Key words:
metabolic syndrome – diabetes mellitus – hypertension – heart rate – obesity
Sources
1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.
2. Berková M. Sledování diastolického plnění levé komory srdeční u diabetiků 1. typu a srovnání diastolických ukazatelů s ukazateli kardiální autonomní neuropatie. Kandidátská disertační práce. Olomouc 2003: 108.
3. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.
4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
5. Gillman MW, Kannel WB, Belanger Aet al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148–1154.
6. Charvát J, Hlaváček K, Vaněček T et al. Výsledky koronarografických nálezů a prognóza nemocných s diabetes mellitus a ischemickou chorobou srdeční. Cor vasa 2001; 43: 483–487.
7. Chlumský J. Vliv kompenzace diabetu na diastolické plnění levé komory. Vnitř Lék 1994; 40: 93–95.
8. Kanel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham Study. Am J Cardiol 1974; 34: 29–34.
9. Kanel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care 1979; 2: 120–126.
10. Maarten L, Simoons MD, Bonneux L. Obesity, cardiology and beyond. J Am Coll Cardiol 2008; 52: 986–987.
11. Madala MC, Franklin BA, Chen AY et al. Obesity and age of first non ST segment elevation myocardial infarction. J Am Coll Cardiol 2008; 52: 979–985.
12. Niles NW, McGrath PD, Malenka D et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularisation. Results from a large regional prospective study. J Am Coll Cardiol 2001; 37: 1008–1015.
13. Norhammar A, Malmberg K. Heart fai-lure and glucose abnormalities: an increasing combination with poor functional capacity and outcome. Eur Heart J 2000; 21: 1293–1294.
14. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11 (Suppl 1): S19–S27.
15. Perušičová J. Diabetické makroangio-patie a mikroangiopatie. Praha: Galén 2003.
16. Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observentional study. BMJ 2000; 321: 405–412.
17. Suskin N, McKelvie RS, Burns RJ. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000; 21: 1368–1375.
18. Swan JW, Walton C, Godsland I et al. Insulin resistance in chronic heart failure. Eur Heart J 1994; 15: 1528–1532.
19. Špinar J, Vítovec J. Přehled nejvýznamnějších studií u hypertenze a diabetes mellitus. Vnitř Lék 1999; 45: 677–679.
20. Špinarová L, Toman J, Meluzín J et al. Diabetes mellitus u chronického srdečního selhání. Cor Vasa 2003: 45: 96.
21. The UKPDS investigators: UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes. Lancet 1998; 352: 837–865.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2009 Issue 7-8
Most read in this issue
- Metabolic syndrome and the liver (NAFLD/NASH)
- Anxious-depressive disorders and metabolic syndrome
- Chronic mild inflammation links obesity, metabolic syndrome, atherosclorosis and diabetes
- Laboratory markers of metabolic syndrome in clinical practice